date:Jun 17, 2014
and become a fully reporting SEC company. Having led Keryx, a company with a market capitalization over $1 billion, Mr. Tarnok has a proven track record as a forward thinking and accomplished leader. As Dyadic further ventures into new pharmaceutical applications, Mike's wealth of knowledge in drug development, manufacturing, marketing and finance will be invaluable.
Mr. Tarnok added, I am impressed with the breadth, scope and number of Dyadic's business opportunities in the company's pipelin